Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 144

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 144
---
 our disclosure controls and
procedures were effective at the reasonable assurance level as of December 31, 2024.

Attestation Report of the Registered Public
Accounting Firm

This annual
report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting.
Management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the Securities
and Exchange Commission that permit smaller reporting companies to provide only management’s report in this annual report.

Management’s Report on Internal Control
Over Financial Reporting

Our CEO and our CFO are responsible for establishing
and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f). Management
conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2024. In making this
assessment, management used the criteria described in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (“COSO”). Our management concluded that our internal controls over financial reporting
were effective based on those criteria, as of December 31, 2024.

Changes in Internal Control over Financial
Reporting

None.

Item 9B. Other Information

(b) Director and Officer
Trading Arrangements

None
of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading
arrangement (as such terms are defined in Item 408 of Regulation S-K) during the three months ended December 31, 2024.

Item 9C. Disclosure Regarding Foreign Jurisdictions
that Prevent Inspections

Not applicable.

67

PART III

Certain information required by Part III is omitted from this Annual
Report because the Company will file a definitive proxy statement within 120 days after the end of its fiscal year pursuant to Regulation 14A
(the Proxy Statement) for its annual meeting of stockholders, and certain information included in the Proxy Statement is incorporated
herein by reference.

Item 10. Directors, Executive Officers and
Corporate Governance

The information required by this Item 10 will be set forth in the
Proxy Statement and is incorporated in this Annual Report by reference.

Item 11. Executive Compensation

The information required by this item will be set forth in the Proxy Statement
and is incorporated in this Annual Report by reference.

Item